173772-63-9

Basic information

• Product Name: 2,4-DICHLORO-3-AMINOPYRIDINE
• Synonyms: 2,4-DICHLORO-3-AMINOPYRIDINE;3-Pyridinamine,2,4-dichloro-(9CI);2,4-Dichloro-3-pyridinamine;2,4-dichloropyridin-3-amine;2,4-dichloropyridin-3-ylaMine
• CAS NO: 173772-63-9
• Molecular Formula: C₅H₄Cl₂N₂
• Molecular Weight: 163.00466
• Product Categories: HALIDE;pharmacetical;Pyridine;Heterocycle-Pyridine series
• Mol File: 173772-63-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 265℃
• Flash Point: 114℃
• Appearance: /
• Density: 1.497
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.72±0.10(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-3-AMINOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-3-AMINOPYRIDINE(173772-63-9)
• EPA Substance Registry System: 2,4-DICHLORO-3-AMINOPYRIDINE(173772-63-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 173772-63-9(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-3-aminopyridine is a chemical compound that is commonly used in the synthesis of pharmaceuticals and agrochemicals. It is a derivative of the pyridine family and has the molecular formula C5H4Cl2N2. This chemical is often used as a building block in the production of various drugs and pesticides due to its ability to react with other compounds to form new substances. It is also known for its potential as a precursor for the synthesis of diverse heterocyclic compounds with various applications in the pharmaceutical and agricultural industries. Additionally, 2,4-Dichloro-3-aminopyridine is considered to have moderate toxicity and is typically handled with care in laboratory settings.

Upstream product

• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 1130155-48-4 (E)-4-(dimethylamino)-2-butenoic acid hydrochloride 
• 1172579-70-2 (S)-2-amino-2-(4-methyltetrahydro-2H-pyran-4-yl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)acetamide 
• 7439-89-6 iron 
• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 626-03-9 3-deazauracil 

Downstream Products

• 91872-08-1 2,4,6-trichloro-[3]pyridylamine 
• 14121-36-9 2,3,4,6-Tetrachloropyridine 
• 950192-61-7 3-amino-4-chloro-2-phenylpyridine 
• 950192-63-9 C₂₄H₂₂ClN₃O₃ 
• 950192-65-1 C₂₄H₂₁N₃O₂S 
• 1422198-91-1 2-phenyl-5-(pyrrolidine-1-yl)oxazolo[5,4-b]pyridine 
• 101560-81-0 5-chloro-2-phenylthiazolo[5,4-b]pyridine 
• 1422198-81-9 5-chloro-2-phenyloxazolo[5,4-b]pyridine 
• 237435-17-5 3-amino-4-chloro-6-methyl-2-(2-phenylethynyl)pyridine 
• 1026076-88-9 7-chloro-5-methyl-2-phenylpyrrolo[3,2-b]pyridine 
• 179056-98-5 3-amino-2,4-dichloro-6-methylpyridine 

Relevant articles and documents

Heterocyclic compound as well as pharmaceutical composition, preparation method, intermediate and application thereof

The invention discloses a heterocyclic compound as well as a pharmaceutical composition, a preparation method, an intermediate and application thereof. The structure of the heterocyclic compound is shown as a formula I, and the heterocyclic compound has CDK7 inhibitory activity and can be used for treating diseases such as tumors.

Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway

The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use in the clinic and the drug-drug interactions with rifampicin have prompted research efforts towards identifying alternative ATP synthesis inhibitors with differentiated mechanisms of action. A biochemical assay was employed to screen AstraZeneca's corporate compound collection to identify the inhibitors of mycobacterial ATP synthesis. The high-throughput screening resulted in the identification of 2,4-diaminoquinazolines as inhibitors of the ATP synthesis pathway. A structure-activity relationship for the quinazolines was established and the knowledge was utilized to morph the quinazoline core into quinoline and pyrazolopyrimidine to expand the scope of chemical diversity. The morphed scaffolds exhibited a 10-fold improvement in enzyme potency and over 100-fold improvement in selectivity against inhibition of mammalian mitochondrial ATP synthesis. These novel compounds were bactericidal and demonstrated growth retardation of Mycobacterium tuberculosis in the acute mouse model of tuberculosis infection.

5-Substituted 1H-pyrrolo[3,2-b]pyridines as inhibitors of gastric acid secretion

A series of novel 1H-pyrrolo[3,2-b]pyridines was prepared relying on a copper iodide catalyzed cyclization of 2-prop-1-ynylpyridin-3-amines. A structure-activity relationship was established focusing on the influence of the substitution pattern in position 1, 3, and 5 of the heterocycle on anti-secretory activity, lipophilicity, and pKa value. Some of the compounds proved to be potent inhibitors of the gastric acid pump.